Hexarelin: The Most Potent GHRP
Growth Hormone Releasing Peptides
2 distinct receptors
Hexarelin is unique among GHRPs in activating both the ghrelin receptor (GHS-R1a) for growth hormone release and the CD36 receptor for cardioprotection, through independent signaling pathways.
Mao et al., Journal of Geriatric Cardiology, 2014
Mao et al., Journal of Geriatric Cardiology, 2014
View as imageHexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) was synthesized in 1994 as a modified hexapeptide growth hormone secretagogue. Among the GHRP family that includes GHRP-2, GHRP-6, and ipamorelin, hexarelin produces the largest absolute growth hormone peak in both animal and human studies.[1] But what makes hexarelin genuinely distinct is not its GH-releasing potency. It is the only GHRP with well-documented dual receptor activity: it activates the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor responsible for GH release, and the scavenger receptor CD36, a cardiac receptor that mediates cardioprotective effects independent of growth hormone.[2] This dual mechanism has made hexarelin a research tool for understanding both the GH axis and cardiac biology, though it has never reached clinical approval. This article covers the peptide chemistry, receptor pharmacology, growth hormone data, cardiovascular research, neuroprotection findings, and limitations. For comparisons between GHRPs, see GHRP-2 vs GHRP-6. For the ghrelin receptor mechanism shared by all GHRPs, see How GHRPs Activate the Ghrelin Receptor. For the appetite effects that distinguish GHRP-6, see GHRP-6 and Hunger.
Key Takeaways
- Hexarelin produces the highest growth hormone peak among synthetic GHRPs in both infant and adult models, with dose-dependent GH release after intravenous, subcutaneous, intranasal, and oral administration (Deghenghi et al., Life Sciences, 1994)
- Unlike other GHRPs, hexarelin activates the CD36 receptor on cardiomyocytes, mediating cardioprotective effects that are independent of growth hormone release (Mao et al., Journal of Geriatric Cardiology, 2014)
- Hexarelin protected rat cardiomyocytes from ischemia-reperfusion injury through IL-1 signaling pathway activation, with effects abolished in CD36 knockout but preserved in GHS-R1a knockout models (Huang et al., International Heart Journal, 2017)
- In neonatal brain injury models, hexarelin reduced brain damage and altered Akt/GSK-3-beta phosphorylation, suggesting neuroprotective potential beyond GH-mediated effects (Brywe et al., Endocrinology, 2005)
- Hexarelin and GHRP-2 produce comparable GH responses that exceed GHRH-stimulated release, but both also elevate ACTH, cortisol, and prolactin, unlike the more GH-selective ipamorelin (Arvat et al., Peptides, 1997)
- Repeated hexarelin administration produces desensitization of GH response within 14-16 weeks, a limitation that distinguishes it from GHRH-based therapies (Conley et al., Journal of Endocrinology, 1998)
Peptide Chemistry: What Makes Hexarelin Different
Hexarelin's sequence (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) shares the core hexapeptide scaffold common to GHRPs but contains a critical modification at position 2: D-2-methyltryptophan (D-2-MeTrp) replaces the D-tryptophan (D-Trp) found in GHRP-6. This single methylation increases GHS-R1a binding affinity and metabolic stability while also conferring the CD36 binding that distinguishes hexarelin from other family members.
The D-amino acid residues at positions 2 and 5 (D-2-MeTrp and D-Phe) protect against enzymatic degradation, giving hexarelin a plasma half-life of approximately 70 minutes after subcutaneous injection, compared to 15-20 minutes for GHRP-6. The C-terminal amidation (Lys-NH2) further enhances receptor binding and stability. The molecular weight of hexarelin is approximately 887 daltons, placing it within the typical size range for synthetic hexapeptide secretagogues.
In a 2024 pharmacological characterization study using dynamic mass redistribution and calcium mobilization assays, hexarelin showed potent GHS-R1a agonist activity alongside GHRP-2, GHRP-6, ipamorelin, and the non-peptide secretagogue MK-0677.[3] All of these compounds activate the same receptor but with different selectivity profiles for downstream effects, reflecting their structural differences and their varying interactions with receptor conformational states. The GHS-R1a receptor displays constitutive activity (signaling even without agonist binding) and can be activated, inhibited, or biased by different ligands. Hexarelin's interaction appears to favor G-protein signaling over beta-arrestin recruitment compared to some other GHS-R1a agonists, though detailed biased agonism studies comparing hexarelin to newer selective compounds are limited. These pharmacological distinctions matter because the ratio of G-protein to beta-arrestin signaling influences both the acute GH release response and the rate of receptor desensitization that ultimately limits hexarelin's chronic utility.
Growth Hormone Release: The Potency Data
Hexarelin was first characterized as a GH secretagogue in 1994, when Deghenghi and colleagues demonstrated dose-dependent GH release in both infant and adult rats. The GH response was reproducible after intravenous, subcutaneous, intranasal, and oral administration, though oral bioavailability was low (approximately 5%).[1]
In a head-to-head comparison, hexarelin and GHRP-2 produced similar strong GH responses that exceeded the response to GHRH alone. However, neither was GH-specific: both stimulated prolactin, ACTH, and cortisol secretion at GH-releasing doses.[4] This secondary hormone stimulation is a consistent finding across studies and represents a meaningful limitation. The ACTH and cortisol elevations are mediated at least partly through arginine vasopressin, not through direct pituitary stimulation, suggesting that hexarelin activates hypothalamic circuits beyond the GH axis.
Hexarelin interacts with the somatostatin system in a complex way. A 1997 study found that somatostatin could partially but not completely suppress hexarelin-induced GH release, indicating that hexarelin's GH-releasing mechanism involves pathways that are at least partially independent of somatostatin inhibition.[5] This partial resistance to somatostatin distinguishes GHRPs from GHRH, whose effects are fully suppressible by somatostatin.
The Desensitization Problem
Repeated hexarelin administration produces a progressive decline in GH response. A 1996 study found that the GH response to hexarelin diminished after repeated daily administration, though the response to GHRH was preserved, indicating that desensitization is specific to the GHS-R1a pathway rather than a generalized pituitary fatigue.[6]
In conscious male rats, continuous hexarelin infusion produced initial GH elevation followed by progressive desensitization, with GH responses declining substantially by 14-16 weeks of treatment.[7] This desensitization is a fundamental limitation for chronic GH-related applications. The ghrelin receptor appears to undergo internalization and downregulation with sustained agonist exposure, a common feature of G-protein coupled receptors but one that effectively limits hexarelin's utility as a long-term GH secretagogue.
The desensitization does not appear to affect the CD36-mediated cardioprotective pathway, which operates through an entirely different receptor system. This has shifted research interest from hexarelin's GH effects (limited by desensitization) toward its cardiovascular effects (potentially sustained).
The CD36 Receptor: Cardioprotection Beyond Growth Hormone
The most distinctive aspect of hexarelin research is its interaction with the CD36 receptor. CD36 is a class B scavenger receptor expressed on cardiomyocytes, microvascular endothelial cells, monocytes/macrophages, and platelets. It has multiple ligands including oxidized LDL, long-chain fatty acids, and thrombospondin. The discovery that hexarelin binds CD36 in the heart was unexpected and has opened a line of research separate from the GH axis entirely.
A comprehensive 2014 review of hexarelin's cardiovascular action established that the peptide's cardioprotective effects are mediated primarily through CD36 rather than GHS-R1a.[2] The critical evidence came from receptor knockout experiments: hexarelin's cardioprotective effects were abolished in CD36 knockout animals but preserved in GHS-R1a knockout animals. This definitively established that the heart protection and the GH release are mediated by different receptors.
In a 2017 study of ischemia-reperfusion injury, hexarelin protected rat cardiomyocytes through interleukin-1 signaling pathway activation, with the protective effect dependent on CD36 engagement and subsequent activation of pro-survival cascades including PI3K/Akt and ERK1/2.[8]
A 2015 review examined the implications of ghrelin and hexarelin in diabetes and diabetes-associated heart disease, finding that hexarelin's CD36-mediated effects on cardiac metabolism and inflammation could be relevant to the cardiac complications of metabolic disease.[9] Diabetic cardiomyopathy involves altered fatty acid metabolism, oxidative stress, and inflammation in cardiomyocytes, all processes that CD36 signaling modulates.
The binding site on CD36 for hexarelin appears to be distinct from the sites used by oxidized LDL and long-chain fatty acids, which means hexarelin does not compete with the receptor's metabolic functions. This is pharmacologically favorable: hexarelin can engage CD36 for cardioprotection without disrupting its role in fatty acid uptake or its scavenging of oxidized lipoproteins. However, it also means the downstream signaling pathways activated by hexarelin-CD36 binding may differ from those activated by other CD36 ligands, complicating the prediction of therapeutic effects from basic receptor biology.
The highest CD36 binding density was found in the cardiac ventricles, followed by atria, aorta, coronary arteries, carotid arteries, endocardium, and vena cava. This distribution pattern maps onto the cardiovascular structures most vulnerable to ischemic injury, suggesting an endogenous protective mechanism that hexarelin may be amplifying pharmacologically. Whether endogenous ligands normally engage CD36 for cardioprotection, and whether hexarelin mimics or enhances this endogenous mechanism, is not yet clear.
The related peptide GHRP-6, which lacks CD36 binding, also showed cardioprotective properties through GHS-R1a-mediated mechanisms. A 2024 study found that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage by activating prosurvival mechanisms, indicating that cardiac protection in the GHRP family involves both CD36-dependent (hexarelin) and GHS-R1a-dependent (GHRP-6) pathways.[10]
Hexarelin in the Context of the GHRP Family
Understanding hexarelin requires situating it within the broader GHRP family. Growth hormone releasing peptides were first synthesized in the late 1970s, beginning with met-enkephalin analogs that were found to stimulate GH secretion. The family expanded through systematic structure-activity relationship studies, producing GHRP-6 (the prototypical member), GHRP-1, GHRP-2, hexarelin, and ipamorelin.
Each GHRP has a different selectivity profile. GHRP-6 is the least potent for GH release but produces the strongest appetite stimulation, a property mediated through ghrelin receptor activation in hypothalamic hunger circuits. GHRP-2 matches hexarelin for GH release potency but lacks the CD36 binding that defines hexarelin's cardiac profile. Ipamorelin is the most GH-selective, releasing growth hormone without meaningful stimulation of ACTH, cortisol, or prolactin, but produces a lower absolute GH peak. Non-peptide ghrelin receptor agonists like MK-0677 (ibutamoren) offer oral bioavailability but activate the ghrelin receptor with a pharmacological profile distinct from the peptide secretagogues.
The clinical trajectories of these compounds diverged. Ipamorelin and GHRP-2 were studied for post-surgical ileus and GH deficiency. MK-0677 accumulated extensive clinical trial data for muscle wasting and Alzheimer disease. Hexarelin reached only early-phase clinical evaluation for GH-related indications before its GH desensitization problem and non-selective hormone release redirected interest toward its cardiovascular properties.
Intranasal hexarelin was tested in 8 prepubertal short children aged 4-11.6 years. At doses of 60 micrograms per kilogram three times daily, hexarelin stimulated IGF-1 secretion and increased mean linear growth velocity from 5.3 centimeters per year to 8.3 centimeters per year. This pilot data demonstrated proof of concept for GH axis stimulation in children but was never followed by larger controlled trials.
The GHRP family also intersects with the broader ghrelin system. Ghrelin, the endogenous ligand of GHS-R1a, was discovered in 1999, years after the synthetic GHRPs were already in use. This unusual sequence, synthetic agonists preceding the natural ligand, meant that GHRPs like hexarelin provided the pharmacological tools used to characterize the ghrelin receptor itself. The receptor was cloned in 1996 as the "growth hormone secretagogue receptor" based on its ability to bind synthetic GHRPs, and only three years later was ghrelin identified as its endogenous ligand. Hexarelin's dual receptor engagement with both GHS-R1a and CD36 continues to provide insights into how the ghrelin signaling system extends beyond simple appetite and GH regulation.
For how ghrelin itself connects appetite, GH release, and the reward system, see Ghrelin: The Hunger Hormone. For how the ghrelin/appetite system intersects with addiction neuroscience, see Ghrelin and Alcohol Craving.
Neuroprotection: A Smaller but Intriguing Dataset
Hexarelin's effects extend to the brain. A 2005 study in neonatal brain injury models found that hexarelin reduced brain damage and altered Akt/glycogen synthase kinase-3-beta (GSK-3-beta) phosphorylation, promoting pro-survival signaling in neurons.[11] The Akt/GSK-3-beta pathway is a central node in neuronal survival signaling, and its activation by hexarelin suggests a neuroprotective mechanism that parallels the cardiac PI3K/Akt activation.
Whether this neuroprotection is mediated through GHS-R1a, CD36, or both is not yet resolved. The GHS-R1a receptor is expressed in hippocampal, hypothalamic, and cortical neurons, and ghrelin itself has demonstrated neuroprotective properties in various models. Hexarelin's additional CD36 binding could provide complementary neuroprotection through a separate pathway, but the receptor knockout studies that clarified the cardiac mechanism have not been replicated in brain injury models.
The ghrelin receptor (GHS-R1a) forms functional complexes with other neurotransmitter receptors that are relevant to brain function. A 2022 study found that GHS-R1a forms complexes with dopamine D1 receptors in the ventral tegmental area, mediating dopaminergic reward responses, suggesting that GHS-R1a agonists like hexarelin could influence reward and motivation circuits.[12] For more on how ghrelin signaling connects to reward, see Ghrelin: The Hunger Hormone.
Hexarelin also attenuated antinociceptive tolerance to morphine in a 2021 rat study, reducing the progressive loss of morphine's pain-relieving effect with repeated use.[13] This finding connects to the broader GHRP/ghrelin system's modulation of opioid pathways and could have implications for pain management, though the data remains preclinical. Opioid tolerance is a central problem in chronic pain treatment, driving dose escalation and increasing overdose risk. If ghrelin receptor agonism can slow or reduce tolerance development, this would represent a meaningful clinical application distinct from GH release.
The neuroprotection findings must be interpreted cautiously. Brain injury and opioid tolerance models involve acute interventions in controlled animal settings. Whether chronic hexarelin administration would provide sustained neuroprotection in human neurodegenerative conditions is entirely speculative. The desensitization that limits GH release with chronic dosing might similarly attenuate neuroprotective effects, though this has not been tested directly. The CD36 pathway, which does not appear to desensitize, could provide a route to sustained neuroprotection if it is indeed involved in the brain effects, but this remains to be determined.
Beyond Hexarelin: Immune and Peripheral Effects
Hexarelin's receptor profile produces effects beyond the brain and heart. The peptide stimulates GH release from peripheral lymphocytes, demonstrating that GHS-R1a is expressed and functional on immune cells.[14] GH produced locally by immune cells has autocrine and paracrine functions in immune regulation, and hexarelin-stimulated lymphocyte GH release suggests a connection between the GH secretagogue system and immune function.
Hexarelin metabolites have been characterized in human urine after nasal administration, providing pharmacokinetic data relevant to both clinical development and anti-doping detection.[15] All GHRPs are prohibited by the World Anti-Doping Agency (WADA) as GH secretagogues, and detection methods have been developed for hexarelin and its metabolites in both blood and urine matrices. The interest in detection reflects the fact that GHRPs have been used in athletic doping to stimulate endogenous GH release, which is harder to detect than exogenous GH administration. Hexarelin's metabolic profile after intranasal dosing has been particularly well-characterized, with specific metabolite signatures enabling reliable detection in anti-doping testing.
The immune effects also connect to an underappreciated aspect of GH biology. Growth hormone has well-established immunomodulatory properties, including enhancement of T-cell proliferation, natural killer cell activity, and macrophage function. If hexarelin stimulates local GH production in lymphocytes, it could modulate immune responses through both direct receptor effects and indirect GH-mediated pathways. This intersection of the ghrelin receptor system with immune function is an area where hexarelin's unique properties (potent GH stimulation plus CD36 engagement on macrophages) could provide insights that other GHRPs cannot.
Limitations and Clinical Status
Hexarelin has never received regulatory approval for any indication. Several factors have limited its clinical development.
Desensitization. The progressive loss of GH response with repeated administration makes hexarelin unsuitable as a chronic GH secretagogue. This limitation applies to all GHRPs to varying degrees but is well-documented for hexarelin specifically. Pulsatile or intermittent dosing protocols may mitigate desensitization, but no long-term clinical data exists to confirm this.
Non-selective hormone release. Hexarelin's stimulation of ACTH, cortisol, and prolactin alongside GH creates unwanted endocrine effects. Ipamorelin, by contrast, demonstrates more GH-selective release without significant ACTH or cortisol elevation, which has made it the preferred research GHRP for GH-specific applications. GHS-R1a agonists like anamorelin and ipamorelin have been studied for cancer-related cachexia, where their GH and appetite-stimulating effects are therapeutically useful, and these compounds have progressed further clinically than hexarelin.[16]
Route of administration. Hexarelin requires injection for reliable bioavailability. Oral and intranasal routes have been tested but produce inconsistent absorption. The development of orally bioavailable ghrelin receptor agonists (MK-0677, capromorelin, anamorelin) has reduced interest in injectable peptide secretagogues.
Cardioprotection without clinical trials. The CD36-mediated cardioprotective data is preclinical. No human clinical trials have tested hexarelin for cardiac indications. The leap from ischemia-reperfusion protection in rat models to clinical cardiology requires human safety and efficacy data that does not exist. Whether hexarelin's CD36 engagement translates to reduced infarct size or improved outcomes in human myocardial ischemia is unknown.
CD36 as a therapeutic target. The CD36-mediated effects raise the question of whether a hexarelin analog optimized for CD36 binding and stripped of GHS-R1a activity could provide cardioprotection without GH-related side effects. No such compound has been developed, but the receptor knockout data provides a clear pharmacological rationale for doing so.
Comparison to emerging GHS-R1a therapeutics. While hexarelin stalled, other ghrelin receptor agonists have progressed. Anamorelin received approval in Japan for cancer cachexia/anorexia in 2021. Capromorelin is approved for appetite stimulation in dogs and is being studied for human applications. These compounds achieve what hexarelin could not for GH-related indications: clinical approval, oral bioavailability, and chronic dosing without intolerable desensitization.
Despite these limitations, hexarelin remains scientifically valuable as a dual-receptor tool compound. Its ability to separately engage GHS-R1a and CD36 has been essential for dissecting the contributions of each receptor to the physiological effects of ghrelin signaling. The CD36 pathway, in particular, represents a mechanism that pure ghrelin receptor agonists cannot access, making hexarelin irreplaceable for that line of investigation. Future research may use hexarelin-derived analogs optimized for CD36 selectivity as a new class of cardioprotective peptides, separate from the GH secretagogue tradition entirely.
The Bottom Line
Hexarelin is the most potent growth hormone releasing peptide in terms of absolute GH peak amplitude, but its most scientifically distinctive feature is dual receptor engagement: GHS-R1a for GH release and CD36 for cardioprotection. The cardiac protection data, confirmed through receptor knockout studies, operates independently of growth hormone and involves PI3K/Akt pro-survival signaling. Neuroprotective effects have been demonstrated in neonatal brain injury models. Clinical limitations include GH response desensitization with repeated dosing, non-selective hormone release (ACTH, cortisol, prolactin alongside GH), and the absence of human clinical trials for cardiovascular or neuroprotective indications. Hexarelin remains a research tool rather than a therapeutic, but its dual receptor pharmacology has generated insights that extend well beyond growth hormone biology.